Sponsor

Orion Corporation, Orion Pharma

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Orion Corporation, Orion Pharma appears in 65 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials65
Recruiting shown2
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
A 2-part Phase 1/2 Open-label Trial on ODM-212NCT07563738 · lead sponsor · 2026-03-27
RECRUITING
Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge TestingNCT05084222 · lead sponsor · 2021-11-11
COMPLETED
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With AsthmaNCT04869384 · lead sponsor · 2021-06-23
COMPLETED
Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in NorwayNCT04663386 · lead sponsor · 2020-12-10
TERMINATED
Inspiratory Flow Parameters With Placebo Easyhaler and Placebo HandiHalerNCT04147572 · lead sponsor · 2019-11-01
COMPLETED
Safety and Pharmacokinetics of ODM-209NCT03878823 · lead sponsor · 2019-04-17
COMPLETED
Salmeterol/Fluticasone Easyhaler in the Treatment of Asthma and COPDNCT03755544 · lead sponsor · 2019-01-16
COMPLETED
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate CancerNCT03436485 · lead sponsor · 2018-03-19
ACTIVE_NOT_RECRUITING
Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)NCT03238482 · lead sponsor · 2017-08-16
COMPLETED
Pharmacokinetic of Levodopa Study in Healthy MalesNCT03140956 · lead sponsor · 2017-04-19
COMPLETED
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide DiskusNCT03060044 · lead sponsor · 2016-07-01
COMPLETED
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)NCT02764125 · lead sponsor · 2016-04-08
COMPLETED
Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort TurbuhalerNCT03073057 · lead sponsor · 2016-01-01
COMPLETED
Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's DiseaseNCT02471196 · lead sponsor · 2015-08-14
COMPLETED
Pharmacokinetic Study in Healthy VolunteersNCT02554734 · lead sponsor · 2015-08-01
COMPLETED
Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate CancerNCT02344017 · lead sponsor · 2015-02-01
COMPLETED
To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference ProductNCT02308098 · lead sponsor · 2014-12-01
COMPLETED
Pharmacokinetic Study in Healthy MalesNCT02312232 · lead sponsor · 2014-11-01
COMPLETED
Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide DiskusNCT02162485 · lead sponsor · 2014-06-01
COMPLETED
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide DiskusNCT01856621 · lead sponsor · 2013-05-01
COMPLETED
Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate CancerNCT01784757 · lead sponsor · 2013-03-01
COMPLETED
Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide DiskusNCT01766843 · lead sponsor · 2013-01-01
COMPLETED
Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at HomeNCT01783132 · lead sponsor · 2012-12-01
TERMINATED
Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder InhalersNCT01668121 · lead sponsor · 2012-08-01
COMPLETED
Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler ForteNCT01627158 · lead sponsor · 2012-06-01
COMPLETED
Comparison of Absorption of Budesonide and Formoterol From Budesonide/Formoterol Easyhaler and Symbicort TurbuhalerNCT01593826 · lead sponsor · 2012-05-01
COMPLETED
Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)NCT01424137 · lead sponsor · 2011-09-01
COMPLETED
Phase I Pharmacokinetic Study (BF-BLOCK)NCT01423305 · lead sponsor · 2011-08-01
COMPLETED
Comparison of Budesonide and Formoterol Absorption From Budesonide/Formoterol Easyhaler and Symbicort TurbuhalerNCT01386996 · lead sponsor · 2011-07-01
COMPLETED
Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001NCT01429064 · lead sponsor · 2011-06-01
COMPLETED
Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor FluctuationsNCT01766258 · lead sponsor · 2011-05-01
COMPLETED
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's DiseaseNCT01324518 · lead sponsor · 2011-04-01
COMPLETED
Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate CancerNCT01317641 · lead sponsor · 2011-03-01
COMPLETED
Comparing Different Levodopa/Carbidopa/Entacapone Treatment RegimensNCT01296464 · lead sponsor · 2011-02-01
COMPLETED
Prospective Multicentre Non-interventional Study of VANTAS® for the Treatment of Patients With Advanced Prostate CancerNCT01574846 · lead sponsor · 2011-01-01
COMPLETED
Pharmacokinetic Pilot Study on Budesonide/Formoterol Device-metered Dry Powder InhalersNCT01181063 · lead sponsor · 2010-08-01
COMPLETED
Levodopa Concentration Profile With Stalevo 75/125 mgNCT01070628 · lead sponsor · 2009-12-01
COMPLETED
Inspiratory Flow Parameters and Handling of Easyhaler and Turbuhaler InhalersNCT00984906 · lead sponsor · 2009-09-01
COMPLETED
Bioequivalence Study of Budesonide/Formoterol Easyhaler and Symbicort Turbohaler in AsthmaticsNCT00964535 · lead sponsor · 2009-09-01
COMPLETED
PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride BindingNCT00562198 · lead sponsor · 2008-01-01
TERMINATED
Study to Evaluate Initiation of Stalevo in Early Wearing-offNCT00462007 · lead sponsor · 2006-09-01
COMPLETED
Stalevo in Early Wearing-Off PatientsNCT00125567 · lead sponsor · 2005-08-01
COMPLETED
Peroral Levosimendan in Chronic Heart FailureNCT00130884 · lead sponsor · 2005-03-01
COMPLETED
Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.NCT00247247 · lead sponsor · 2002-12-01
COMPLETED
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.NCT00219388 · lead sponsor · 2002-11-01
COMPLETED
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · collaborator · 2024-05-20
RECRUITING
A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)NCT06566989 · collaborator · 2024-09-19
COMPLETED
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)NCT06136598 · collaborator · 2024-01-30
COMPLETED
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)NCT06104449 · collaborator · 2023-11-14
COMPLETED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerNCT04736199 · collaborator · 2021-02-23
COMPLETED
Effect of Levosimendan or Placebo on Exercise in Advanced Chronic Heart FailureNCT03576677 · collaborator · 2019-08-01
UNKNOWN
Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart FailureNCT03437226 · collaborator · 2018-03-08
UNKNOWN
Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male VolunteersNCT03237416 · collaborator · 2017-08-02
COMPLETED
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · collaborator · 2016-11-30
COMPLETED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · collaborator · 2014-09-12
COMPLETED
Preoperative levosimendán and Hip FractureNCT02972918 · collaborator · 2014-05-01
COMPLETED
Levosimendan Pharmacokinetics in ChildrenNCT01704131 · collaborator · 2012-11-01
UNKNOWN
Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)NCT02261948 · collaborator · 2012-09-01
COMPLETED
Real Life Effectiveness of Easyhaler (Orion)NCT02048930 · collaborator · 2012-09-01
COMPLETED
Preoperative Levosimendan and Heart FailureNCT01022983 · collaborator · 2011-04-01
WITHDRAWN

Drugs studied in this sponsor's trials

18 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Orion Corporation, Orion Pharma as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
levosimendan10
placebo8
dexamethasone3
prednisone3
Stalevo3
budesonide / formoterol2
docetaxel2
fludrocortisone2
levosimendan RxCUI 73107 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 10 trials placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 8 trials dexamethasone RxCUI 3264 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 3 trials prednisone RxCUI 8640 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 3 trials Stalevo RxCUI 1372713 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials budesonide / formoterol RxCUI 389132 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 2 trials fludrocortisone RxCUI 4452 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials fludrocortisone acetate RxCUI 165516 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 2 trials hydrocortisone RxCUI 5492 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials midazolam RxCUI 6960 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials cabazitaxel RxCUI 996051 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial carbidopa RxCUI 2019 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial dabigatran etexilate RxCUI 1037042 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial dobutamine RxCUI 3616 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial levosimendan 2.5 MG/ML RxCUI 901045 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial olaparib RxCUI 1597582 · Lead sponsor in 0 linked trial(s) · 1 currently recruiting 1 trial sotorasib RxCUI 2550714 · Lead sponsor in 1 linked trial(s) · 1 currently recruiting 1 trial

Sponsor roles

lead sponsor45
collaborator20
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.